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Echocardiographic Predictors of Adverse
Outcomes After Continuous Left Ventricular
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John A. Schirger, MD,* Sudhir S. Kushwaha, MD,* Naveen L. Pereira, MD,*
Soon J. Park, MD†
Rochester, Minnesota
O B J E C T I V E S The purpose of the study was to identify echocardiographic predictors of adverse
outcome in patients implanted with continuous-ﬂow left ventricular assist devices (LVAD).
B A C KG ROUND Continuous ﬂow LVAD have become part of the standard of care for the treatment
of advanced heart failure. However, knowledge of echocardiographic predictors of outcome after LVAD
are lacking.
METHOD S Overall, 83 patients received continuous-ﬂow LVAD (HeartMate II, Thoratec Corporation,
Pleasanton, California) from February 2007 to June 2010. The LVAD database, containing various echocar-
diographic parameters, was examined to analyze their inﬂuence on in-hospital mortality, a compound cardiac
event (in-hospital mortality or acute right ventricular [RV] dysfunction), and long-term mortality.
R E S U L T S Eight patients died before discharge (operative mortality 9.6%), and another 15 patients were
considered to have acute RV dysfunction immediately after surgery. Patients with relatively small left
ventricular end-diastolic diameters (63 mm) had signiﬁcantly higher risk for in-hospital mortality (odds ratio
[OR]: 0.9; 95% conﬁdence interval [CI]: 0.83 to 0.99; p  0.04) or occurrence of the compound cardiac event
(OR: 0.89; 95% CI: 0.84 to 0.95; p  0.001). The most signiﬁcant predictor of outcome was the decreased
timing interval between the onset and the cessation of tricuspid regurgitation ﬂow corrected for heart rate
(TRDc), a surrogate for early systolic equalization of RV and right atrial pressure. Short TRDc predicted
in-hospital mortality (OR: 0.85; 95% CI: 0.74 to 0.97; p 0.01) and the compound cardiac event (OR: 0.83; 95%
CI: 0.74 to 0.91; p 0.0001). Multivariate analysis based on a logistic regression model demonstrated that the
accuracy of predicting the 30-day compound adverse outcome was improved with the addition of
echocardiographic variables when added to the commonly used hemodynamic or clinical scores. TRDc
predicted long-term survival, with adjusted risk ratios of 0.89 for death from any cause (95% CI: 0.83 to 0.96;
p  0.003) and 0.88 for cardiac-related death (95% CI: 0.77 to 0.98; p  0.03).
CONC L U S I O N S The presence of either a relatively small left ventricle (63 mm) or early systolic
equalization of RV and right atrial pressure (short TRDc) demonstrated by echocardiography is
associated with increased 30-day morbidity and mortality. Prediction of early adverse outcomes by
echocardiographic parameters is additive to laboratory or hemodynamic variables. (J Am Coll Cardiol
Img 2011;4:211–22) © 2011 by the American College of Cardiology Foundation
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212eft ventricular (LV) assist device (LVAD) ther-
apy for patients with advanced heart failure has
been proven to improve survival over medical
therapy (1). Continuous-flow LVAD have
eplaced pulsatile LVAD because they have been
hown to have better patient survival and less device
ailure (2,3). However, there is still significant
orbidity and mortality in patients treated with
VAD. It is important to identify risk factors for
uch adverse outcomes and modify current practice
o reduce them (4). Pre-operative echocardiography
as a major role in the management of patients with
VAD and is frequently used to assist in patient
election for LVAD therapy. Because LVAD ther-
apy is effective in replacing LV function,
we postulated that variables related to LV
function may not be predictive of adverse
outcomes after surgery. In contrast, other
factors, especially those related to LV
dimensions or to right ventricular (RV)
function, may have a strong influence. We
examined various pre-operative echocar-
diographic, hemodynamic, and clinical
variables for their impact on mortality and
RV dysfunction after surgery. We also
examined different clinical scores (5–7) to
determine whether they were additive to
the echocardiographic parameters for the
prediction of clinical outcomes.
M E T H O D S
Patient population. We identified all 83
consecutive patients who received the
HeartMate II continuous-flow LVAD
(Thoratec Corporation, Pleasanton, Cali-
fornia) for either destination or bridge to
transplant therapy between February 2007
and June 2010. We defined operative mor-
tality as death within 30 days of LVAD
implantation or during the index hospitalization
and acute right-heart failure as a need for an RV
assist device or inotropic support for more than 7
days post-operatively.
Clinical and demographic data. Pre-operative clini-
al, echocardiographic, hemodynamic, and labora-
ory data as well as data concerning post-operative
dverse events, right-heart failure, length of stay, and
hort-term and long-term mortality were abstracted
rom the medical records. Laboratory evaluations were
ll performed within 24 h before surgery. Echocardio-
raphic examinations were performed in all patients,
t
t
d-
-
forsually within the month before surgery (median 16ays, 25th and 75 percentiles 7 and 36 days). Hemo-
ynamic catheterizations were performed in 80 of 83
atients (96.4%), usually within a week before surgery
median 4 days, 25th and 75th percentiles 2 and 9
ays). The study protocol was reviewed and approved
y the institutional review board at the Mayo Clinic in
ochester, Minnesota.
Echocardiographic measurements. Two-dimensional
transthoracic echocardiography was performed in a
standard manner. LV diameters and ejection frac-
tion were measured as recommended (8). Right
atrial (RA) pressure was estimated by the inferior
vena cava diameter and its response to inspiration
(9). RV function and tricuspid regurgitation (TR)
and mitral regurgitation (MR) severity were quali-
tatively graded using a 4-point scale (normal, mild,
moderate, or severe) using all views. The severity of
TR was assessed using color flow imaging and vena
contracta width (10). MR was quantitatively as-
sessed using the proximal isovelocity surface area
method whenever it was considered to be more than
mild (11). RV function was assessed using tissue
Doppler assessment of lateral tricuspid annular mo-
tion (12), systolic TR duration (13), and the right
index of myocardial performance (RIMP) (14).
We corrected the time intervals of RV ejection
time and the time between the onset and the
cessation of TR flow (13) for heart rate using the
correction formula time of TR flow corrected for
heart rate (TRDc)  TR flow time/RR, as
previously suggested by others (Fig. 1C) (14,15).
Interobserver and intraobserver variability. Interob-
server variability was determined by a second inde-
pendent blinded observer who measured the echo-
cardiographic variables in 15 randomly selected
patients. Intraobserver variability was determined
by having the first observer who measured the data
in all patients remeasure the timing intervals in 15
patients at least 3 months apart. Interobserver and
intraobserver variability were assessed using the
Bland-Altman method and the within-subject coef-
ficient of variation. The within-subject coefficient of
variation (calculated as the ratio of the standard
deviation of the measurement difference to the mean
value of all measurements) provides a scale-free, unit-
less estimate of variation expressed as a percentage.
We measured intraobserver and interobserver repro-
ducibility for TRDc, RV ejection time corrected for
heart rate, and RIMP and expressed them using the
coefficient of variation. Values of p  0.05 were
considered statistically significant.
Statistical analysis. Unless otherwise specified, dataA B B R E V I A T I O N S
A N D A C R O N YM S
CI confidence interval
EROA effective regurgitan
orifice area
LV left ventricular
LVAD left ventricular assis
device
LVEDD left ventricular en
diastolic diameter
LVESD left ventricular end
systolic diameter
MRmitral regurgitation
NYHA New York Heart
Association
OR odds ratio
RA right atrial
RIMP right index of
myocardial performance
RV right ventricular
TR tricuspid regurgitation
TRDc time of tricuspid
regurgitation flow correctedare presented as mean  SD or as percentages.
T
s
o
t
w
s
R
b
r
t
c
p
c
m
p
fi
w
t
d
t
w
d
e
R
o
d
a
m
p
w
w
i
u
N
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 3 , 2 0 1 1
M A R C H 2 0 1 1 : 2 1 1 – 2 2
Topilsky et al.
Echocardiographic Predictors of LVAD Outcome
213Comparisons between groups were performed using
analysis of variance, Student t test, or the chi-square
test as appropriate. To analyze independent determi-
nants of the compound 30-day adverse event (in-
hospital mortality or RV dysfunction), multivariate
analysis based on a logistic regression model (with the
combined end point as the dependent variable and the
different echocardiographic variables as independent
variables) was performed. Variables assessing echocar-
diographic predictors were entered first, and those
measuring right-heart catheterization measurements
or the different clinical scores were added consecu-
tively to the models. The first entry criterion in the
multivariate analysis was a univariate p value 0.05.
o correct for possible overfitting of the model con-
idering that we observed only 23 events, we selected
nly variables that supported our stated hypothesis
hat variables related to LV function or filling pressure
ould not be predictive of adverse outcomes after
urgery but that factors related to LV dimensions or to
V function might have a strong influence. On the
asis of those assumptions, we excluded MR effective
egurgitant orifice area (EROA) and TR velocity from
he model. To detect multicollinearity, we first used
orrelation factor analyses to determine if any pairs of
redictor variables were highly correlated (correlation
oefficients over 0.9) and therefore likely to result in
ulticollinearity. If any such pairs were found, 1 of the
redictor variables was selected for inclusion in the
nal analysis and the other was ignored. The variable
ith the lowest p value was chosen to be included in
he analysis. We then proceeded with multicollinearity
iagnostic statistics and examined the variance infla-
ion factor. Variance inflation factors exceeding 10
ere regarded as indicating multicollinearity and were
ropped from the model. Using these procedures, we
xcluded LV systolic diameter, RIMP, and TR minus
V ejection time from the model and were left with
nly 2 echocardiographic variables (LV end-diastolic
iameter [LVEDD] and TRDc). Actuarial survival
nalysis was performed using the Kaplan-Meier
ethod, and the results were compared between the
re-specified groups using log-rank analysis. Patients
ere censored for heart transplantation. All p values
ere 2 sided, and p values 0.05 were considered to
ndicate statistical significance. All data were analyzed
sing JMP version 8.0 (SAS Institute Inc., Cary,
orth Carolina).
R E S U L T S
Baseline characteristics. Table 1 shows the baseline
characteristics of the patients enrolled, both overallFigure 1. Duration of the TR Signal on Continuous-Wave Doppler
(A) A patient with short tricuspid regurgitation (TR) duration. The increased right
atrial (RA) pressure causes the tricuspid valve to open earlier, on the steeper curve
of the ventricular relaxation curve, thereby shortening the isovolumic relaxation
(IVR) interval and TR ﬂow duration. Furthermore, a reduction in diastolic pulmonary
artery (PA) to end-diastolic right ventricular (RV) pressure difference shortens the
“isovolumic contraction (IVC) time.” (B) Prolonged TR duration in another patient
with end-stage dilated cardiomyopathy. The TR signal has a higher peak velocity
and systolic RV pressure. The pressure in the right ventricle at the time of pulmo-
nary valve closure must fall from a higher point to reach the pressure of the right
atrium, lengthening the IVR period. Furthermore, the increase in diastolic pulmonary
pressure to end-diastolic RV pressure difference lengthens the IVC period. Note that
the TR signal ends with a concave, prolonged contour consistent with a markedly
delayed relaxation of the right ventricle. (C) Calculation of TR duration corrected for
heart rate (TRDc). We ﬁrst measured the time interval of the duration of the TR sig-
nal in milliseconds (red arrow  450 ms). We then measured the RR interval in sec-
onds using the electrocardiographic tracing (yellow arrow  0.9 seconds). We thenused the formula TRDc  TR duration/RR interval (450/0.9  473 ms).
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214Table 1. Baseline Characteristics of All Patients and Divided by Those With and Without Adverse 30-Day Cardiac Outcomes (In-Hospital Mortality, Need
for RVAD, or Post-Operative Inotropic Support >168 H) Before LVAD Implantation
All Patients
Adverse Cardiac 30-Day
Outcome Normal 30-Day Outcome
Characteristic (n  83) (n  23) (n  60) p Value
Age (yrs) 62.9 12.0 60.4 10.0 64.2 13.0 0.10
Men/women (%) 80.7/19.3 88/12 80/20 0.40
NYHA functional class 0.02
IIb 40% 26% 45%
IV 60% 74% 55%
Prior sternotomy (%) 51 48 53 0.60
Pre-operative IABP (%) 31 56 25 0.008
Pre-operative inotropic use (%) 74 65 68 0.40
Destination therapy (%) 67 52 70 0.04
Type of cardiomyopathy 0.006†
Ischemic heart disease 54% 31% 63%
Dilated cardiomyopathy 34% 48% 32%
Restrictive heart disease 10% 17% 7%
Other 2% 4% 8%
Heart rate (beats/min) 77.1 14.0 78.9 15.0 76.4 15.0 0.50
Systolic blood pressure (mm Hg) 99.4 14.0 102.2 18.0 98.4 13.0 0.30
Diastolic blood pressure (mm Hg) 62.4 10.0 65.7 10.0 63.7 11.0 0.50
Hemoglobin (g/dl) 11.8 2.0 11.5 1.0 12.0 2.0 0.30
Bilirubin (mg/dl) 1.2 0.7 1.2 0.9 1.2 0.6 0.70
BUN (mg/dl) 31.0 16.0 34.2 19.0 29.7 15.0 0.30
Creatinine (mg/dl) 1.4 0.5 1.5 0.6 1.4 0.5 0.30
NT-BNP (pg/ml) 5,673 5,229 6,570 6,704 5,270 4,499 0.50
Lietz-Miller score 9.7 5.7 12.5 6.5 8.5 5.0 0.005
Matthews score 1.1 2.2 2.0 3.0 0.8 1.7 0.03
Kormos score 1.8 1.9 2.7 2.4 1.4 1.5 0.005
Echocardiography
LV diastolic diameter (mm) 67.2 9.0 61.2 9.0 69.4 9.0 0.0003
LV systolic diameter (mm) 60.8 9.0 54.7 9.0 63.2 8.0 0.0006
Septal thickness (mm) 10.2 2.0 11.3 3.0 10.2 3.0 0.20
Posterior wall thickness (mm) 9.8 2.0 9.8 1.0 10.0 2.0 0.60
Ejection fraction (%) 19.7 7.0 19.1 11.0 20.1 8.0 0.70
Cardiac output (l/min) 4.1 1.0 4.0 1.0 4.1 1.0 0.80
Cardiac index (l/min/m2) 2.2 0.8 2.2 1.0 2.2 0.7 0.80
LA volume (cm3) 133.0 49.0 134.0 34.0 132.6 54.0 0.90
LA volume index (cm3/m2) 68.2 27.0 66.9 19.0 68.7 30.0 0.80
E/e= ratio* 27.5 12.0 23.6 10.0 28.8 12.0 0.10
Deceleration time# 135.9 30.0 126.8 27.0 138.7 31.0 0.20
TR velocity (m/s) 3.0 0.6 2.8 0.7 3.1 0.6 0.03
Estimated RA pressure¶ (mm Hg) 14.9 5.0 15.0 5.0 14.8 5.0 0.90
Tricuspid valve lateral annular velocity (m/s) 0.08 0.03 0.08 0.03 0.08 0.03 0.80
RV dysfunction  moderate 67% 68% 66% 0.90
RIMP 0.57 0.2 0.43 0.2 0.61 0.2 0.003
TRDc‡ (ms) 466 69 416 56 486 64 0.0001
RV ejection time corrected (ms) 302 39 296 40 306 38 0.40
TR  RV ejection time§ (ms) 150 56 109.6 44.0 165.4 53.0 0.0002
MR 0.02
None 8% 8% 8%
Mild 30% 42% 26%(Continued on next page)
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215and divided into 2 groups, those (23 patients)
positive for the 30-day compound adverse outcome
(operative mortality or acute RV dysfunction) and
those (60 patients) considered to have normal
30-day outcomes. The mean age was 62.9  12.4
years, and 80.7% were men. We calculated and
included the clinical scores proposed by Lietz et al.
(7), Matthews et al. (5), and Kormos et al. (6) for all
patients (Table 1).
The parameters estimating LV systolic function
and LV filling pressures were not different between
Table 1. Continued
Al
Characteristic (
Moderate
Severe
MR EROA (PISA) (cm2) 0.
TR
None
Mild
Moderate
Severe
TR vena contracta width (mm) 4
Hemodynamic parameters
Mean RA pressure (mm Hg) 15
Mean PA pressure (mm Hg) 36
PVR (Wood units) 4
RV dP/dt 4
Mean wedge pressure (mm Hg) 23
Cardiac output (l/min) 3
Cardiac index (l/min/m2) 1
Matching for NYHA functional class, destination therapy,
type of cardiomyopathy, Lietz-Miller score, and
mean RA pressure
Age (yrs) 60
Men/women 8
NYHA functional class
IIIb
IV
Destination therapy
Type of cardiomyopathy
Ischemic heart disease
Dilated cardiomyopathy
Restrictive heart disease
Other
Lietz-Miller score 12
Mean RA pressure (mm Hg) 18
Data are expressed as mean  SD or as (%). *Ratio of E velocity of mitral inﬂow t
disease. ‡Interval between cessation and onset of TR ﬂow divided by the squa
and cessation of RV outﬂow divided by the square root of the RR interval. ¶Es
BUN  blood urea nitrogen; EROA  effective regurgitant oriﬁce area; IABP  i
regurgitation; NT-BNP  N-terminal brain natriuretic peptide; NYHA  New Yor
resistance; RA  right atrial; RIMP  right index of myocardial performance;
regurgitation duration corrected for heart rate.the groups. LVEDD and left ventricular end-systolic diameter (LVESD) (61.2  8.7 mm vs.
69.4 8.8 mm, p 0.0003, and 54.7 9.3 mm vs.
63.2  8.5 mm, p  0.0006, respectively) were
smaller in patients with adverse 30-day outcomes.
TR was worse (TR vena contracta width 4.9  2.5
mm vs. 3.7  2.4 mm, p  0.05), but the EROA
of MR was smaller (0.23  0.05 cm2 vs. 0.37 
0.16 cm2, p  0.05) in patients with adverse
utcomes.
TRDc was significantly shorter in patients with
dverse outcomes (416  56 ms vs. 486  64 ms,
tients
Adverse Cardiac 30-Day
Outcome Normal 30-Day Outc
83) (n  23) (n  60)
29% 22%
21% 44%
0.15 0.23 0.05 0.37 0.16
6% 22%
23% 37%
18% 12%
53% 29%
2.0 4.9 3.0 3.7 2.0
7.0 18.6 8.0 14.1 5.0
9.0 33.6 9.0 37.0 9.0
3.0 3.5 3.0 4.4 3.0
207 442 219 499 202
7.0 23.5 7.0 23.5 7.0
1.0 4.0 1.0 3.8 1.0
0.5 2.0 0.5 1.9 0.5
11.5 59.8 10.4 60.3 12.8
15% 87%/13% 83%/17%
23% 23%
77% 77%
% 52.1% 60.8%
22% 39%
48% 44%
17% 9%
13% 8%
5.2 12.4 6.5 12.4 3.6
6.8 18.6 8.3 17.6 5.0
rly diastolic relaxation tissue velocity of medial annulus. †P value for the difference
ot of the RR interval. §Difference between TR ﬂow time and RV ejection time. In
ion of RA pressure using the inferior vena cava method. #Deceleration time of e
aortic balloon pump; LA  left atrial; LV  left ventricular; LVAD  left ventricular
rt Association; PA  pulmonary artery; PISA  proximal isovelocity surface area; P
right ventricular; RVAD  right ventricular assist device; TR  tricuspid regurgl Pa ome
n  p Value
23%
39%
35 0.05
0.03
9%
34%
13%
44%
.0 0.05
.4 0.007
.0 0.15
.2 0.20
83 0.30
.5 0.90
.9 0.40
.9 0.60
.0 0.90
5%/ 0.70
1.00
23%
77%
56.5 0.20
0.50
30%
46%
13%
10%
.4 0.90
.1 0.60
o ea in ratio of ischemic heart
re ro terval between the onset
timat arly mitral inﬂow.
ntra- assist device; MR  mitral
k Hea VR  pulmonary vascular
RV  itation; TRDc  tricuspidp  0.0001). The RV ejection period corrected for
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216heart rate was not different between the groups, so
the derived sum of RV isovolumetric contraction
time and isovolumetric relaxation time (calculated
by subtracting RV ejection time from TR flow
duration) was significantly shorter in patients with
adverse outcomes (109.6  44 ms vs. 165.4  53
s, p  0.0002). The RIMP ratio was significantly
ecreased (pseudonormalized) in patients with ad-
erse outcomes (0.43  0.2 vs. 0.61  0.2, p 
.003).
The only difference in hemodynamic baseline
haracteristics was higher RA pressure (18.6  8.3
m Hg vs. 14.1  5.5 mm Hg, p  0.007) in
atients with adverse 30-day outcomes. Lietz, Mat-
hews, and Kormos scores (5–7) were significantly
igher in patients with adverse outcomes as well
Table 1).
Thirty-day post-operative outcomes. Table 2 shows
ost-operative outcomes in all patients and divided
nto patients with and without 30-day adverse
utcomes. Eight patients died before discharge
operative mortality 9.6%). The causes of death
ncluded multiple-organ failure in 2 patients, un-
ontrolled right-heart failure in 2, hyperperfusion
Table 2. Post-Operative 30-Day Outcomes and Hospital Courses
Adverse 30-Day Outcomes
All Patients A
Outcome (n  83)
Operative mortality (%) 9.6
Cardiopulmonary bypass time (min) 103.3 34.0
Post-operative red blood cell transfusion (U) 10.5 10.0
Need for RVAD (%) 3.6
Infection (%)† 49
Bleeding (%)* 68
Prolonged intubation (%)# 23
Arrhythmia (%)¶ 20
Acute renal failure (%)‡ 16
Acute cerebral event (%) 12
Hepatic dysfunction (%)§ 18
Thromboembolic event (%)** 11
Dialysis (%) 10
Mean RA pressure (mm Hg)†† 12.8 5.4
Mean PA pressure (mm Hg)†† 26.8 7.2
Pump ﬂow (l/min)‡‡ 5.1 0.7
LOS (days) 17 (11, 27)
Duration of inotropic support (h) 114 (66, 166)
RV failure (%) 24
LOS  30 days (%) 17
Data are expressed as (%), as mean  SD, or as median (25th percentile, 75th
requiring intravenous antibiotics. ‡Renal failure requiring dialysis or increase in
bilirubin  5.0 mg/dl after surgery. Any stroke, brain hemorrhage, or hyperpe
#Mechanical ventilation for 1 week or need for tracheostomy. **Any embolic
taking out the pulmonary artery catheter. ‡‡Pump ﬂow by the LVAD monitor
LOS  length of stay; other abbreviations as in Table 1.rain injury in 2, sepsis in 1, and uncontrollable
leeding after argatroban treatment for heparin-
nduced thrombocytopenia in 1. The median length
f stay after LVAD surgery was 17.5 days (25th and
5th percentiles 11 and 27.5 days), and the median
uration of inotropic support was 114.5 h (25th and
5th percentiles 66.5 and 166.5 h). Post-operative
VAD flow (before discharge or death) and pul-
onary artery pressure tended to be lower, but RA
ressure (the last hemodynamic measurement be-
ore taking out the Swan-Ganz catheter) was sig-
ificantly higher in patients with adverse outcomes,
uggestive of RV dysfunction.
Echocardiographic predictors of adverse outcomes.
Univariate analysis (Table 3) showed that none of
the parameters related to LV function or filling
pressure influenced the compound event or early
mortality. Patients with relatively small ventricles
had significantly higher risk for the compound
event (prolonged inotropic support or death):
LVEDD (odds ratio [OR]: 0.89; 95% confidence
interval [CI]: 0.84 to 0.95) and LVESD (OR: 0.89;
95% CI: 0.83 to 0.95), p  0.001 for both. A small
ventricle was also associated with increased risk for
All Patients and Divided by Patients With and Without
rse 30-Day Outcome Normal 30-Day Outcome
(n  23) (n  60) p Value
35.0 0.0 0.0001
116.7 33.0 98.0 33.0 0.03
15.9 15.0 8.5 6.0 0.002
13.0 0.0 0.004
74 38 0.001
77 65 0.30
73 5 0.0001
36 13 0.02
36 8 0.004
32 5 0.002
41 10 0.002
14 10 0.60
37 2 0.0001
16.2 5.4 11.6 4.8 0.003
29.6 9.4 25.7 5.8 0.06
4.8 0.7 5.2 0.7 0.07
33 (23, 41) 15 (10, 23) 0.0001
372 (247, 696) 76 (54, 120) 0.0001
87 0 0.0001
57 10 0.0002
centile). *Bleeding requiring blood transfusion 24 h after surgery. †Infection
atinine to 2 mg/dl or by 50% from baseline. §Liver enzymes  300 U/l or
n injury. ¶Hemodynamically signiﬁcant arrhythmia or requiring cardioversion.
nt after surgery. ††Hemodynamic data represent the last measurement before
e discharge or death.of
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217in-hospital mortality (OR: 0.9; 95% CI: 0.83 to
0.99; and OR: 0.9; 95% CI: 0.81 to 0.98), for every
increase in LVEDD and LVESD (p  0.05 for
oth). To define which LV diameter should be
onsidered relatively small and carrying increased
isk after LVAD surgery, we dichotomized
VEDD at the 25th (LVEDD  60 mm), 33rd
60 mm  LVEDD  63 mm), 50th (63 mm 
VEDD  67 mm), 66th (67 mm  LVEDD 
Table 3. Univariate Analysis of Predictors of Short-Term Mortal
LVAD Implantation
Variable (Death or RV F
Echocardiography
LV diastolic diameter (mm) 0.89 (0.84–0
LV systolic diameter (mm) 0.89 (0.83–0
Septal thickness (mm) 1.1 (0.94–1
Posterior wall thickness (mm) 0.94 (0.71–1
Ejection fraction (%) 0.98 (0.92–1
Cardiac output (l/min) 0.96 (0.62–1
Cardiac index (l/min/m2) 0.93 (0.41–1
LA volume (cc) 1.0 (0.99–1
LA volume index (cc/m2) 0.99 (0.97–1
E/e= ratio* 0.95 (0.89–1
Deceleration time§ 0.98 (0.96–1
TR velocity (m/sec) 0.4 (0.16–0
Estimated RA pressure¶ 1.0 (0.91–1
Tricuspid lateral annular velocity (m/sec) 0.97 (0.79–1
RV dysfunction  moderate 1.1 (0.6–1.8
RIMP (0.1 increase) 0.63 (0.44–0
TRDc† for 10 ms 0.83 (0.74–0
RV ejection time 0.99 (0.97–1
TR  RV ejection time‡ 0.78 (0.66–0
MR EROA (PISA) 0.38 (0.1–0.9
TR vena contracta width 1.2 (0.95–1
Clinical and demographic
Age 0.97 (0.94–1
Gender (male) 1.7 (0.7–2.8
NYHA functional class IV 2.7 (0.92–9
Pre-operative IABP 2.0 (1.2–3.3
Hemoglobin 0.86 (0.66–1
Bilirubin 1.1 (0.6–2.2
BUN 1.0 (0.98–1
Creatinine 1.6 (0.6–4.3
NT-BNP (per 100 pg/ml) 1.0 (0.98–1
Lietz-Miller score 1.1 (1.04–1
Matthews score 1.24 (1.01–1
Kormos score 1.5 (1.1–2.1
Right-heart catheterization
Mean RA pressure (mm Hg) 1.1 (1.02–1
Mean PA pressure (mm Hg) 0.96 (0.91–1
PVR (WU) 0.88 (0.72–1
RV dP/dt 0.99 (0.99–1
Mean wedge pressure (mm Hg) 0.99 (0.93–1
Cardiac index (lit/min/m2) 1.3 (0.5–3.5
Univariate analysis in the matched group
LV diastolic diameter (mm) 0.88 (0.8–0.9
LV systolic diameter (mm) 0.89 (0.82–0
RIMP (0.1 increase) 0.64 (0.4–0.9
TRDc† for 10 ms 0.82 (0.69–0
TR  RV ejection time‡ 0.97 (0.95–0
*Ratio of E velocity of mitral inﬂow to early diastolic relaxation tissue velocity o
square root of the RR interval. ‡Difference between TR ﬂow time and RV ejecti
cessation of RV outﬂow divided by the square root of the RR interval. ¶Estimat
CI  conﬁdence interval; OR  odds ratio; other abbreviations as in Table 1.1 mm), 75th (67 mm  LVEDD  74 mm), and ibove (LVEDD  74 mm) percentiles. We then
alculated the risk for the compound cardiac
vent for each group. We found that the risk for
dverse outcomes almost tripled when LVEDD
ecreased below 63 mm (the risk for adverse
utcomes was 64%, 60%, 25%, 13%, 14%, and
0%, respectively, from the smallest to the largest
uartile; p  0.005).
In contrast, the EROA of MR had a positive
r Compound 30-Day Adverse Event in Patients Undergoing
OR (95% CI)
re) p Value Early Mortality p Value
0.0003 0.9 (0.83–0.99) 0.04
0.0007 0.9 (0.81–0.98) 0.01
0.20 1.05 (0.77–1.33) 0.70
0.60 0.87 (0.6–1.3) 0.50
0.70 0.93 (0.81–1.03) 0.20
0.80 1.14 (0.62–1.9) 0.60
0.80 0.91 (0.25–2.3) 0.90
0.90 1.0 (0.98–1.02) 0.90
0.80 1.0 (0.96–1.03) 0.90
0.10 1.03 (0.95–1.12) 0.40
0.20 1.01 (0.98–1.05) 0.40
0.03 0.6 (0.2–2.1) 0.40
0.90 1.02 (0.9–1.2) 0.80
0.80 0.96 (0.65–1.3) 0.90
0.80 0.5 (0.1–1.25) 0.15
0.001 0.86 (0.57–1.2) 0.40
0.0001 0.85 (0.74–0.97) 0.01
0.30 0.97 (0.96–1.00) 0.056
0.0001 0.85 (0.72–1.0) 0.05
0.03 0.42 (0.08–1.16) 0.10
0.10 1.2 (0.87–1.7) 0.30
0.10 1.02 (0.96–1.11) 0.40
0.40 1.6 (0.5–5.6) 0.60
0.07 0.77 (0.26–1.5) 0.40
0.007 1.9 (0.9–4.3) 0.08
0.30 0.82 (0.54–1.22) 0.30
0.70 1.08 (0.3–2.7) 0.80
0.30 1.05 (1.01–1.1) 0.004
0.30 5.1 (1.3–22.8) 0.02
0.50 1.03 (1.01–1.06) 0.003
0.005 1.05 (0.92–1.2) 0.40
0.04 1.25 (0.94–1.6) 0.10
0.006 1.4 (1.0–2.1) 0.04
0.007 1.07 (0.96–1.2) 0.20
0.10 0.97 (0.89–1.06) 0.60
0.20 0.78 (0.5–1.08) 0.15
0.30
0.90 1.01 (0.9–1.13) 0.80
0.60 1.5 (0.33–6.6) 0.60
0.0007 1.07 (0.98–1.19) 0.09
0.003 1.08 (0.99–1.19) 0.06
0.02 1.0 (0.65–1.56) 0.90
0.001 1.14 (0.99–1.36) 0.06
0.001 1.12 (0.94–1.36) 0.20
dial annulus. †Interval between cessation and onset of TR ﬂow divided by the
me. §Deceleration time of early mitral inﬂow. Interval between the onset and
f RA pressure using the inferior vena cava method.ity o
ailu
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218p  0.03 for every increase in EROA by 1 cm2).
The most significant predictor of the clinical out-
come was TRDc. Short TRDc was predictive of the
compound 30-day outcome (OR: 0.83; 95% CI:
0.74 to 0.91; p  0.0001) and in-hospital mortality
(OR: 0.85; 95% CI: 0.74 to 0.97; p  0.01).
The derivatives of TR flow time, including the
shortened sum of isovolumic contraction and relax-
ation, and RIMP were all predictors of worst
compound 30-day outcome but not of early mor-
tality (Table 3).
Multivariate analysis based on logistic regression
using only echocardiographic parameters demon-
strated that the accuracy of predicting the 30-day
compound adverse outcome was maximal when
incorporating LVEDD and TRDc (Table 4). RA
pressure and all the clinical scores were predictive of
the combined event on univariate analysis (Table 3)
and marginally increased the C-index of the echo-
cardiographic logistic model (from 0.81 for echo-
cardiography alone to 0.83) (Table 4).
To further evaluate whether the proposed echo-
cardiographic variables retained their predictive
value after adjusting for the other baseline differ-
ences between the groups (New York Heart Asso-
ciation [NYHA] functional class, the percentage
of destination therapy, etiology of heart disease,
Lietz-Miller score, and right-heart pressure), we
matched each subject in the group positive for the
30-day compound adverse outcome with a patient
from the group considered to have normal 30-day
outcomes for age, gender, and all baseline differ-
ences (Table 1).
We found that the predictive value of LVEDD
(OR: 0.88; 95% CI: 0.8 to 0.95; p  0.0007),
LVESD (OR: 0.89; 95% CI: 0.82 to 0.96; p 
Table 4. Multivariate Analysis of Predictors of Compound 30-Da
Prolonged Inotropic Support) in Patients Undergoing LVAD Imp
Echocardiography
Alone
Adjusted for RA
Pressure
LV diastolic diameter 0.06 0.06
TRDc* 0.001 0.006
RA pressure 0.6
Lietz-Miller score
Matthews score
Kormos score
p Value 0.0001 0.0001
Hosmer-Lemeshow 0.98 0.97
C-index 0.81 0.83
*Interval between onset and cessation of TR ﬂow divided by the square root o
Abbreviations as in Table 1.0.003), TRDc (OR: 0.82; 95% CI: 0.69 to 0.93;
p  0.001), TR  RV ejection time (OR: 0.97;
95% CI: 0.95 to 0.99; p  0.001), and RIMP (OR:
0.64; 95% CI: 0.4 to 0.93; p  0.02) for the
combined 30-day adverse end point remained sig-
nificant (Table 3) even after the matching process.
Intraobserver and interobserver variability. Compari-
on of intraobserver timing intervals showed good
greement between measurements: TRDc (mean
ifference 0.71  15.4 ms, r  0.97, p  0.86), RV
jection time corrected for heart rate (mean differ-
nce 0.1  9.8 ms, r  0.98, p  0.97), and
IMP (mean difference 0.003  0.066, r  0.95,
 0.86). The Bland-Altman plot showed a
andom scatter of points around 0, indicating no
ystematic bias or measurement error proportional
o the measurement value. Measurement variability
within-subject coefficient of variation and 95% CI
f the Bland-Altman method) for measurements of
ntraobserver differences was as follows: TRDc,
.3% and 8.9 ms; RV ejection time corrected for
eart rate, 3.2% and 5.6 ms; and RIMP, 10.1%
nd 0.04.
Comparison of interobserver timing intervals
howed good agreement as well: TRDc (mean
ifference3.7 25.6 ms, r 0.92, p 0.60), RV
ejection time corrected for heart rate (mean differ-
ence 5.0 10.0 ms, r 0.97, p 0.10), and RIMP
(mean difference 0.04  0.12, r  0.84, p 
0.30). Measurement variability for measurements of
interobserver differences was as follows: TRDc, 5.0%
and 14.8 ms; RV ejection time corrected for heart
rate, 3.3% and 5.8 ms; and RIMP, 17% and 0.06.
Long-term mortality. The mean follow-up duration
fter surgery was 270.1  262.8 days. Eighteen
atients (21.7%) died and 11 patients had their
dverse Event (In-Hospital Mortality, Need for RVAD, or
tation
Adjusted for Lietz-Miller
Score
Adjusted for
Matthews Score
Adjusted for
Kormos Score
0.05 0.08 0.08
0.005 0.001 0.01
0.09
0.2
0.6
0.0001 0.0001 0.0001
0.5 0.7 0.7
0.83 0.83 0.83
RR interval.y A
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f the
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219LVAD explanted for heart transplantation during
the follow-up period. The causes of death in pa-
tients surviving the index hospitalization were trau-
matic head injury in 3, hemorrhagic stroke in 2, and
unexplained sudden death in 2; 1 patient decided to
withdraw support. The actuarial survival rate was
77.4  5.5% and 62.6  9.2% at 1 and 2 years,
espectively.
TRDc and its derivative RV ejection time  TR
flow time were the only echocardiographic predic-
tors of long-term survival, with adjusted risk ratios
for death from any cause of 0.89 (95% CI: 0.83 to
0.96; p 0.003) and 0.9 (95% CI: 0.82 to 0.99; p
0.03), respectively. Of note, neither RA pressure
nor any of the clinical scores predicted long-term
mortality in our models. We defined cardiovascular
mortality as mortality related to intractable heart
failure or arrhythmic death. TRDc was predictive of
cardiac-related death (OR: 0.88; 95% CI: 0.77 to
0.98; p  0.03) but not of noncardiac causes of
death (OR: 0.92; 95% CI: 0.82 to 1.04; p  0.20).
The echocardiographic parameters were first di-
chotomized at the 10th, 25th, 33rd, 50th, 66th,
75th, and 90th percentiles, and the percentile value
with the lowest p value was chosen as the threshold
for the Kaplan-Meier analyses.
The dichotomization took place at the 50th
percentile for TRDc (461 ms). TRDc461 ms was
a strong predictor of mortality, with an adjusted OR
of 2.3 (95% CI: 1.3 to 4.9; p 0.03) compared with
a longer TRDc. The 2-year survival rate was sig-
nificantly lower in those with TRDc461 ms (28.8
 21.1%) compared with patients with longer
TRDc (85.7  8.5%) (Fig. 2). We compared
NYHA functional class and 6-min walking distance
3 months after LVAD surgery in patients with
prolonged or short TRDc before surgery. More
patients were in NYHA functional class III or IV 3
months after surgery among those with TRDc
461 ms before surgery compared with patients
with prolonged TRDc (58.8% vs. 19.2%, p 
0.008). There was a trend for decreased 6-min
walking distance in patients with pre-operative
TRDc 461 ms (278 vs. 366.2 m, p  0.10) 3
months after surgery.
The dichotomization for LVEDD took place at
the 33rd percentile (63 mm), and we classified
patients as having relatively small left ventricles
(LVEDD  63 mm) or larger left ventricles
(LVEDD  63 mm). Although a small increase in
mortality could be appreciated, the survival curves
coalesced after 18 months (Fig. 3).D I S C U S S I O N
This study is among the first to report echocardio-
graphic predictors of outcomes after LVAD sur-
gery. We found that early adverse events were
predicted by the presence of a relatively small left
ventricle and shorter TR flow duration at the time
of LVAD therapy. It was interesting to note that
none of the LV functional parameters influenced
Figure 2. Kaplan-Meier Estimates of the Mean  SE Rates of Ov
Patients After LVAD Surgery According to the TRDc
The 1-year and 2-year survival rates were low in patients with tricu
duration corrected for heart rate (TRDc) 461 ms and markedly im
with longer TRDc. Values in parentheses are survival rates at 1 and
ventricular assist device.
Figure 3. Kaplan-Meier Estimates of the Mean  SE Rates of Ov
Patients After LVAD Surgery According to LV Diameter
Although an increase in early mortality could be appreciated, the s
coalesced after 18 months. Values are survival rates at 1 year. LV erall Survival Among
spid regurgitation
proved in patients
2 years. LVAD  lefterall Survival Among
urvival curves
left ventricular;LVAD  left ventricular assist device.
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220outcomes. However, it is not surprising, given how
effective an LVAD is in replacing LV function.
Long-term mortality was predicted by a short
TRDc (or its derivatives) as well.
LV diameter. A relatively small LV internal dimen-
ion (63 mm) was found to pose an early postop-
rative problem. In patients with LVAD, an in-
rease in revolutions per minute may cause a
iminution of the LV cavity, shifting the interven-
ricular septum to the left. This in turn impairs RV
utput, diminishing the LV cavity even further.
his worsening spiral, sometimes referred to as the
suck-down event,” may cause the septum to en-
roach upon the inflow cannula, resulting in ven-
ricular arrhythmias or drastically decreasing
VAD preload. We believe that a relatively smaller
eft ventricle may increase the risk for such events.
o minimize this risk, our practice in setting the
peed early post-operatively is to use a ramped
peed study using echocardiographic guidance be-
ore discharge. We generally use a fixed speed
etting that falls midway between the minimal and
aximal speeds on the basis of changes in ventric-
lar dimensions, the position of the interventricular
eptum, and the frequency of aortic valve opening.
Patients with relatively small, hypertrophic left
ventricle may present unique issues during surgery.
In 2 patients, we had to perform a limited myo-
mectomy of mid-septal muscle away from the
septum to relieve the inflow tract to the pump. It is
reassuring to note that the impact of a relatively
small ventricle (63 mm) on outcomes is short
lived and that the actuarial survival after more than
18 months is comparable with that in patients with
larger left ventricles (Fig. 3). We believe that the
size of the left ventricle should not be considered a
contraindication to this sometimes crucial therapy.
However, LVAD implantation in patients with
relatively small left ventricles should be considered
higher risk surgery and be performed only at centers
with high volume and expertise.
Predictors of RV dysfunction and mortality. RV dys-
unction is very common in patients with severe LV
ailure and was shown to contribute to perioperative
ortality (2,3,7) as well as decreased long-term survival.
In the present study, TRDc was found to be the
trongest echocardiographic predictor of short-term
nd long-term outcomes.
An increased RIMP ratio was previously shown to
redict outcomes in patients with primary pulmonary
ypertension and restrictive and dilated cardiomyop-
thy (13,14,16). Evidence of a prolonged RV systole
corresponding to the duration of holosystolic TR, including the periods of isovolumic contraction and
elaxation), was shown to predict adverse outcomes in
atients with heart failure (13). To our surprise, we
ound that in our patient population, a short (pseudo-
ormalized) duration of TR was the best predictor of
otal and cardiac mortality.
There are a few principal differences between our
atients and the patients described by others
13,14,16). First, all patients in our study had
nd-stage heart failure (NYHA functional class IIIb
r IV). Second, 44% of our patients had severe TR
efore LVAD surgery.
During the early phases of RV dysfunction, as
he rate of contraction and relaxation decreases, the
sovolumic contraction and relaxation periods be-
ome prolonged. Furthermore, the pulmonary ar-
ery pressure usually increases because of increased
V filling pressure. The increase in end-diastolic
ulmonary pressure without a concomitant increase
n end-diastolic RV pressure results in increased
sovolumic contraction time because the pressure in
he right ventricle must rise to a higher point to reach
he pressure in the pulmonary artery immediately after
ricuspid valve closure (Fig. 1B). Furthermore, the
ncrease in pulmonary artery systolic pressure results
n an equal rise in RV systolic pressure, so once the
ulmonary valve has closed the pressure in the right
entricle must fall from a higher point to reach the
ressure of the right atrium, increasing isovolumic
elaxation and holosystolic periods even further
Fig. 1B). The increase in the systolic and isovolu-
ic period is expected as long as the RV end-
iastolic pressure and RA pressure are within nor-
al limits and ejection time is preserved. In patients
ith extreme heart failure, RV peak systolic pres-
ure may decrease secondary to the markedly di-
inished contractility and stroke volume. The ejec-
ion period usually shortens (evidence of decreased
troke volume), and the end-diastolic pulmonary
rtery pressure and end-systolic RV pressure may
all. Furthermore, end-diastolic RV pressure and
nd-systolic RA pressure (V wave) increase, de-
reasing the pressure differences from the time of
ricuspid valve closure to pulmonary valve opening
nd pulmonary valve closure to tricuspid valve
pening, respectively (Fig. 1A). Those changes in
ressure difference shorten isovolumic contraction,
sovolumic relaxation, and the holosystolic time
nterval (Fig. 1A). One should also note that
lthough they are called isovolumic indexes, there
re in fact large changes of ventricular volume
uring these time intervals, when tricuspid valve
nsufficiency flow is significant Thus, the main
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221determinant of “isovolumic relaxation time” may
cease to be the rate of ventricular relaxation
(14,16,17) but may be determined by the end-
systolic RA pressure (V wave), causing the tricuspid
valve to open earlier, on the steeper curve of
ventricular relaxation, thereby shortening the “iso-
volumic” relaxation interval and the derived holo-
systolic period even further (Fig. 1A).
To analyze the significance of each of the Doppler
time events, we compared them with the hemody-
namic indexes in 20 patients in whom the echocar-
diographic and hemodynamic evaluations were per-
formed 48 h apart (Table 5). A short TR flow
duration was correlated with high RA pressure and a
low RV to RA pressure difference, implying markedly
increased RA pressure and reduced systolic pressure
generation, consistent with a right ventricle working
on the “flat portion” of its Frank-Starling curve and
advanced RV diastolic dysfunction (Table 5).
In conclusion, we believe that the TRDc is a
U-shaped risk factor in patients with right-heart
disease. Increased duration is a risk factor in the
early stages of disease (evidence of impaired relax-
ation), but a “pseudonormalized” TRDc, reflecting
increased RV filling pressure, implies advanced RV
failure and predicts the worst outcome. Of interest, we
have shown that patients after LVAD surgery with
prolonged TR duration have excellent 2-year survival
(85.7  8.5%) and 3-month functional outcomes,
ost probably related to the recovery of RV function.
Increase in Lietz-Miller, Matthews, and Kormos
cores were associated with a higher prevalence of
0-day mortality or severe RV dysfunction. This is
onsistent with previous studies (7,18–21). Our
verall Lietz-Miller, Matthews, and Kormos scores
ere 9.7  5.7, 1.1  2.2, and 1.8  1.9,
Table 5. Correlation of Hemodynamic Parameters With Echocar
Hemodynamic
Variable
Correlation With
TRDc
Correlation With RV
Time Correcte
RA V-wave 0.39 0.2
RA A-wave 0.2 0.37
RA mean pressure 0.46* 0.03
RV systolic pressure 0.51* 0.39
RV diastolic pressure 0.02 0.41
PA mean pressure 0.39 0.02
RV dP/dt 0.05 0.13
Stroke volume 0.18 0.68‡
RV PP 0.72‡ 0.36
PVR 0.45* 0.37
PAP-RA mean 0.74‡ 0.01
*p  0.05; †p  0.01; ‡p  0.001.
PAP  pulmonary artery pressure; PP  pulse pressure; other abbreviations as inespectively, with only a minority of patients strati-
ed as high risk. This is probably one of the reasons
or our low perioperative mortality. It also seems to
mply a progress in our patient selection process,
ositively influenced by the introduction of the scores.
mportantly, echocardiographic analysis has added
alue to clinical and hemodynamic risk assessment in
atients requiring LVAD. We believe that the most
mportant factor in reducing the morbidity and mor-
ality of LVAD therapy may be a timely institution of
urgery before the development of profound RV
ysfunction, evidenced by early equalization of RV
nd RA pressure.
Study limitations. Because of the relatively small
umber of patients, some potentially important risk
actors might not have been entered into the mul-
ivariate analysis model. The results of the present
tudy were based on a retrospective analysis, which
arries limitations associated with the data source.
iven the exploratory nature of the results and the
elatively limited number of patients in the multi-
ariate model, validation in larger patient samples
ill be required. Our use of TR flow to define the
V holosystolic period includes the time equivalent
o the sum of isovolumic contraction, isovolumic
elaxation periods, and ventricular contraction, but
ot the electromechanical delay. Regurgitant flow
ay end before tricuspid valve closure, thereby
nderestimating the duration of systole. However,
his is likely not a substantial phenomenon.
C O N C L U S I O N S
Early mortality and need for prolonged inotropic
support after LVAD surgery seem to be predomi-
nantly determined by a relatively smaller left ven-
raphic Doppler–Derived Time Variables
tion Correlation With
RIMP
Correlation With TR Time  RV
Ejection Time
Co
0.55† 0.71‡
0.3 0.6†
0.54* 0.67‡
0.52* 0.23
0.16 0.003
0.22 0.08
0.36 0.48*
0.15 0.2
0.85‡ 0.83‡
0.64† 0.42
0.65† 0.62†diog
Ejec
d
rrelation With Peak
TR Velocity
0.02
0.13
0.06
0.71‡
0.14
0.61†
0.5‡
0.25
0.83‡
0.46*
0.68‡Table 1.
a
p
c
P
R
M
G
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 3 , 2 0 1 1
M A R C H 2 0 1 1 : 2 1 1 – 2 2
Topilsky et al.
Echocardiographic Predictors of LVAD Outcome
222tricle (63 mm) and the degree of RV dysfunction,
reflected by rapid equalization of RV and RA
pressure (TRDc  461 ms). Prediction of early
dverse outcomes is improved by echocardiographic
arameters when added to the previously suggested
linical scores or invasive hemodynamic variables.
atients with no evidence of early equalization of
V and RA pressure during systole are expected to8. Lang RM, Bierig M, Devereux RB, et
al. Recommendations for chamber
1
1
1
1
1
ular function. J Am
1996;9:838–47.after LVAD surgery. Given the extensive model
and exploratory nature of the results, validation in
larger patient samples is required.
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